The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir‑Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women

Thumbnail Image
Files
The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women.pdf (959.83 KB)
Date
2020
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Drug Safety
Abstract
In May 2018, the World Health Organization and other regulatory authorities released a safety alert for dolutegravir related to a risk of neural tube defects among women exposed to dolutegravir at the time of conception. Models of how drug safety information can be shared effectively in the shortest time are necessary to prevent interruptions of public health programs. We sought to describe an implementation process to inform and support women already on dolutegravir-based regimens at the time of conception to make informed choices following the safety alert of a potential teratogenicity risk. We describe the choices made by women, as well as determine the factors associated with women’s choices to switch off dolutegravir.
Description
Keywords
Women, Urban HIV Clinic, Dolutegravir-Based Regimens, Conception
Citation
Laker, E. A. O., Arinaitwe, A., Owarwo, N., Onzia, A., Nasasira, B., Wailagala, A., ... & Lamorde, M. (2020). The potential teratogenicity alert for women conceiving on dolutegravir-based regimens: an assessment of risk communication by an urban HIV clinic in Uganda and choices made by women. Drug Safety, 43, 1133-1140.https://doi.org/10.1007/s40264-020-00974-9
URI
https://nru.uncst.go.ug/handle/123456789/8841
Collections
Medical and Health Sciences